PARIS, Jan 7 (Reuters) - French health regulator HAS said on
Friday that GSK's Xevudy treatment was promising against
COVID-19 variants such as Omicron as it gave the treatment early
access.
HAS said in a statement the drug featured a mechanism which
suggested that its efficacy could be maintained on variants of
the virus, including the Omicron variant.
(Reporting by Tassilo Hummel
Editing by GV De Clercq)